Mylan

Adamis stock surges on release of EpiPen alternative
Adamis stock surges on release of EpiPen alternative
Marketwatch
Adamis
Mylan
Sandoz
EpiPens
Symjepi
Flag link:
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Pharmaceutical Business Review
Ironwood Pharmaceuticals
Mylan
patents
Linzess
Flag link:
Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Fierce Pharma
Novartis
Sandoz
generics
Symjepi
EpiPens
Teva Pharmaceutical
Mylan
Flag link:
Teva launches EpiPen generic at same price as Mylan's version
Teva launches EpiPen generic at same price as Mylan's version
Biopharma Dive
Teva Pharmaceutical
Mylan
EpiPens
generics
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Mylan, Theravance win FDA approval for COPD drug
Mylan, Theravance win FDA approval for COPD drug
Biopharma Dive
Theravance
Mylan
Yupelri
COPD
FDA
Flag link:
Mylan N.V. Improves in the Third Quarter Thanks to International Sales
Mylan N.V. Improves in the Third Quarter Thanks to International Sales
Motley Fool
Mylan
earnings
Flag link:
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Endpoints
Coherus
Neulasta
Mylan
biosimilars
Amgen
Flag link:
Early November Brings More Quarterly Reports
Early November Brings More Quarterly Reports
BioSpace
earnings
Akcea
Mylan
Eli Lilly
Regeneron
Flag link:
Momenta starts countdown to biosimilars exit
Momenta starts countdown to biosimilars exit
EP Vantage
Momenta Pharmaceuticals
Mylan
biosimilars
Flag link:
5th Humira biosimilar approved in EU as market entry nears
5th Humira biosimilar approved in EU as market entry nears
Biopharma Dive
Europe
biosimilars
AbbVie
Humira
Mylan
Hulio
Flag link:
FDA extends EpiPen expiration date to ease shortages
FDA extends EpiPen expiration date to ease shortages
Biopharma Dive
Mylan
drug shortages
FDA
EpiPens
Flag link:
Mylan's EpiPen supply woes drag on
Mylan's EpiPen supply woes drag on
Biopharma Dive
Mylan
Pfizer
EpiPens
drug shortages
Flag link:
FDA Approves New Generic Version Of The EpiPen For Allergic Reactions
FDA Approves New Generic Version Of The EpiPen For Allergic Reactions
NPR
EpiPens
generics
Teva Pharmaceutical
Mylan
allergic reaction
Flag link:
Mylan Launches First Adcirca Generic, Stock Moves Up
Mylan Launches First Adcirca Generic, Stock Moves Up
Market Realist
Mylan
tadalafil
generics
PAH
Adcirca
United Therapeutics
Flag link:
Mylan signs U.S. license deal on Humira with AbbVie
Mylan signs U.S. license deal on Humira with AbbVie
Yahoo/Reuters
AbbVie
Mylan
biosimilars
Humira
Flag link:
Mylan decimates the list price of its Copaxone copy. But why?
Mylan decimates the list price of its Copaxone copy. But why?
Fierce Pharma
Mylan
drug pricing
Copaxone
Flag link:
Mylan launches generic drug-delivery patch for dementia patients
Mylan launches generic drug-delivery patch for dementia patients
Drug Delivery Business News
Mylan
rivastigmine
generics
Novartis
Exelon
dementia
Alzheimer's disease
Parkinson's Disease
Flag link:
Novartis steps in to compete with Mylan’s Epipen
Novartis steps in to compete with Mylan’s Epipen
Drug Delivery Business News
Adamis Pharmaceuticals
Novartis
Sandoz
Symjepi
Mylan
EpiPens
Flag link:
GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL
GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL
Endpoints
Mylan
FDA
Advair
GSK
complete response letter
Flag link:

Pages